Skip to main content
. Author manuscript; available in PMC: 2013 Jul 6.
Published in final edited form as: Vaccine. 2012 May 23;30(32):4849–4858. doi: 10.1016/j.vaccine.2012.05.006

Figure 2. Binding of anti-CPSIII mAbs to intact GBS, neuraminidase-treated GBS, or purified CPSIII.

Figure 2

Elisa plates were coated with intact or neuraminidase treated GBS, or with purified capsular polysaccharide. Mabs were incubated in the wells at 3 μg/ml and detected with alkaline phosphatase-conjugated anti-mouse Ig. Data are the absorbance at 405nm, mean and SEM.